CNO
CNO Financial Group, Inc.
CNO has slightly lower modeled downside risk, despite its lower overall score.
JPM
JPMorgan Chase & Co.
JPM has the edge over CNO overall, supported by stronger valuation and stronger fundamentals.
CNO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CNO's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNO.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
CNO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $28.30 | -51% |
| Fair | 9.1x | $39.72 | -31% |
| Forward | 11x | $57.44 | — |
| Current | 13x | $57.44 | — |
| Expensive | 15x | $66.35 | +16% |
Historical ranges are pointers, not guarantees.
CNO's PE is in its expensive range at 13x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its fair range.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM has the edge over CNO in the historical PE scenario, which offers more potential upside but is not a forecast.
CNO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CNO's earnings to grow and its profitability to improve, with its revenue holding steady.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
CNO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.03 | +15% |
| Q3 2026 | $4.38 | +53% |
| Q2 2026 | $2.91 | +7.4% |
| Q1 2026 | $2.49 | -13% |
| Q4 2025 | $2.23 | -40% |
| Q3 2025 | $2.86 | +15% |
| Q2 2025 | $2.71 | -30% |
| Q1 2025 | $2.86 | -17% |
| Q4 2024 | $3.74 | +55% |
CNO earned $4.38 per share over the past year, up 53% from the year before.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over CNO on earnings, with more consistent year-over-year improvement.
CNO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | -8.6% |
| Q2 2026 | $1.3B | +12% |
| Q1 2026 | $1B | +2.5% |
| Q4 2025 | $1.1B | +4.2% |
| Q3 2025 | $1.2B | +5.2% |
| Q2 2025 | $1.2B | +8% |
| Q1 2025 | $1B | -13% |
| Q4 2024 | $1.1B | -6.3% |
CNO's revenue grew through 2024 and has held roughly level since: $1.1B last quarter, down 8.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +6.6 points |
| Q2 2026 | 12% | +2 points |
| Q1 2026 | 13% | +2.2 points |
| Q4 2025 | 15% | -0.7 points |
| Q3 2025 | 14% | +0.1 points |
| Q2 2025 | 9.8% | -4.2 points |
| Q1 2025 | 10% | +4 points |
| Q4 2024 | 16% | +1.2 points |
CNO's operating margin was 20% last quarter, up 6.6 points from the same quarter a year ago, near the top of its range since 2019.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM has the edge over CNO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over CNO on profitability, with a higher operating margin.
CNO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $242M | +22% |
| Q2 2026 | $156.6M | +7.6% |
| Q1 2026 | $148.8M | +8.9% |
| Q4 2025 | $195.7M | +2.5% |
| Q3 2025 | $197.8M | -14% |
| Q2 2025 | $145.5M | +31% |
| Q1 2025 | $136.7M | +45% |
| Q4 2024 | $191M | +8.1% |
CNO has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
CNO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -699K shares |
| 1 year | -4.4% | -4.3M shares |
| 3 years | -18% | -20.2M shares |
| 5 years | -27% | -34.8M shares |
| Available history | -40% | -62.9M shares |
CNO has the edge over JPM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $59.5M |
| Q2 2026 | $60.9M |
| Q1 2026 | $73.3M |
| Q4 2025 | $60.2M |
| Q3 2025 | $60.6M |
| Q2 2025 | $100.3M |
| Q1 2025 | $110.3M |
| Q4 2024 | $91.7M |
CNO spent $254M buying back its own shares over the past year, down 30% from the year before.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has 2.7B diluted shares, down 3.1% from a year ago, with $24.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
CNO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -2.4x | Net Cash |
CNO has the edge over JPM on leverage, with a lower net debt burden relative to earnings.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
CNO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 74.8 | Neutral |
CNO's weekly RSI is 63 (neutral) and its Stochastic is 75 (neutral).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
CNO PE vs Financial Services Sector
| Metric | CNO | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.7% above |
| PE % | 72 | 63 | 9 pts above |
CNO has the edge over JPM on valuation relative to its sector.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
CNO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $55.0 | 4.5% above |
| 20 week MA | $54.6 | 5.2% above |
| 50 week MA | $48.1 | 19% above |
| 100 week MA | $43.5 | 32% above |
| 200 week MA | $35.4 | 62% above |
CNO has the edge over JPM on trend strength, trading above more of its moving averages.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
CNO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $22.8 | +25% |
| 2021 | $22.8 | $24.0 | +5% |
| 2022 | $24.0 | $22.9 | -4.6% |
| 2023 | $22.9 | $27.9 | +22% |
| 2024 | $27.9 | $37.3 | +34% |
| 2025 | $37.3 | $43.3 | +16% |
| 2026 YTD | $43.3 | $57.4 | +33% |
CNO has the edge over JPM on returns for 2026, with the stronger performance.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.